The analysis, which tracked patients in routine clinical practice, revealed that participants treated with fezolinetant reported a reduction in sleep disturbances as early as four weeks into treatment. By the 12-week mark, objective measurements collected via wearable devices showed a mean decrease of 2.6 nighttime awakenings. These findings align with patient-reported outcomes, which tracked a shift from mild sleep disturbance levels to a state of no significant disturbance over the same period.

Prof. Marla Shapiro of the University of Toronto, who led the presentation, noted that these results provide a clearer picture of how the drug impacts daily life beyond symptom management. Beyond sleep, the study confirmed statistically significant improvements in vasomotor symptoms, including hot flashes and night sweats, with no new safety signals reported. The findings bolster existing clinical trial evidence and are supported by ongoing observational studies in Germany and Australia, aimed at better understanding long-term outcomes for women managing menopause-related health challenges.